Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Effect of apolipoprotein A-1 treatment on platelet-derived extracellular vesicle modulation in atherosclerotic mouse
EF 2021-22
Résumé
Dre Martel and her team suggested that apolipoprotein A-1 (apoA-1) improves lymphatic transport in mice and decreases exacerbation of atherosclerosis. This effect of apoA-1 appears to be mediated by an increase in platelet adhesion to the lymphatic vascular endothelium. Although lymph is normally devoid of platelets, they demonstrated that platelet-derived extracellular vesicles (PEVs) were highly abundant in mice lymph and may exert a similar role within the lymphatic vessel wall. Preliminary results indicate that PEVs appear to protect the lymphatic endothelium from invading agents in vitro.The aim of this study is to determine whether apoA-1 potentiates the beneficial effect of PEVs on lymphatic function under atherosclerotic conditions. To this end, pro-atherosclerotic LDLr-/- mice on a high-fat diet will be treated with apoA-1 followed by PEVs, produced from isolated human platelets. Lymphatic function will be analyzed by assessing immune cell transport, skin draining lymph node clearance, migration and molecular transport by FITC, lymphatic contractions, and lymphatic vessel permeability. In addition, the effect of pretreatment with apoA-1 on the adhesion of PEVs and their internalization into a TNF-a treated lymphatic endothelium will be measured by IF and flow cytometry. Variations levels of markers involved in lymphatic function (qPCR and WB), ROS production and changes in the cell cycle will be assessed. ApoA-1 treatment followed by PEVs on the lymphatic endothelial permeability will also be assessed by Transwell assay and the expression of markers characterizing lymphatic junctions.In conclusion, this project will identify a new therapeutic approach in the treatment of lymphatic dysfunction which contributes to cardiovascular diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466688
Name
Amri Nada
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effect of apolipoprotein A-1 treatment on platelet-derived extracellular vesicle modulation in atherosclerotic mouse
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apolipoprotein A-I; Atherosclerosis; Extracellular Vesicles; Inflammation; Lymphatic System; Permeability; Platelets
Abstract
Dre Martel and her team suggested that apolipoprotein A-1 (apoA-1) improves lymphatic transport in mice and decreases exacerbation of atherosclerosis. This effect of apoA-1 appears to be mediated by an increase in platelet adhesion to the lymphatic vascular endothelium. Although lymph is normally devoid of platelets, they demonstrated that platelet-derived extracellular vesicles (PEVs) were highly abundant in mice lymph and may exert a similar role within the lymphatic vessel wall. Preliminary results indicate that PEVs appear to protect the lymphatic endothelium from invading agents in vitro.The aim of this study is to determine whether apoA-1 potentiates the beneficial effect of PEVs on lymphatic function under atherosclerotic conditions. To this end, pro-atherosclerotic LDLr-/- mice on a high-fat diet will be treated with apoA-1 followed by PEVs, produced from isolated human platelets. Lymphatic function will be analyzed by assessing immune cell transport, skin draining lymph node clearance, migration and molecular transport by FITC, lymphatic contractions, and lymphatic vessel permeability. In addition, the effect of pretreatment with apoA-1 on the adhesion of PEVs and their internalization into a TNF-a treated lymphatic endothelium will be measured by IF and flow cytometry. Variations levels of markers involved in lymphatic function (qPCR and WB), ROS production and changes in the cell cycle will be assessed. ApoA-1 treatment followed by PEVs on the lymphatic endothelial permeability will also be assessed by Transwell assay and the expression of markers characterizing lymphatic junctions.In conclusion, this project will identify a new therapeutic approach in the treatment of lymphatic dysfunction which contributes to cardiovascular diseases.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Amri, Nada
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~